Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Moodys
QuintilesIMS
McKesson
Cipla
Daiichi Sankyo
Harvard Business School
Mallinckrodt
UBS

Generated: December 16, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ISTODAX

« Back to Dashboard

Clinical Trials for Istodax

Trial ID Title Status Sponsor Phase Summary
NCT00053963 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed National Cancer Institute (NCI) Phase 1 This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die
NCT00062075 Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well romidepsin works in treating patients with relapsed or refractory acute myeloid leukemia. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00079443 FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma Terminated National Cancer Institute (NCI) Phase 2 This phase I/II trial is studying the best dose of FR901228 when given together with rituximab and fludarabine and to see how well FR901228 works alone in treating patients with relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228 and fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Rituximab may increase the effectiveness of chemotherapy drugs by making cancer cells more sensitive to the drugs.
NCT00084461 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated National Cancer Institute (NCI) Phase 2 Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00084682 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed National Cancer Institute (NCI) Phase 2 This phase II trial is studying how well FR901228 works in treating patients with unresectable recurrent or metastatic squamous cell carcinoma (cancer) of the head and neck. Drugs used in chemotherapy such as FR901228 work in different ways to stop tumor cells from dividing so they stop growing or die.
NCT00085540 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed National Cancer Institute (NCI) Phase 1/Phase 2 This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Istodax

Condition Name

Condition Name for Istodax
Intervention Trials
Lymphoma 5
Lymphoma, T-Cell, Peripheral 3
Cutaneous T-cell Lymphoma 3
Recurrent Mantle Cell Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Istodax
Intervention Trials
Lymphoma 24
Lymphoma, T-Cell 18
Lymphoma, T-Cell, Peripheral 13
Lymphoma, Non-Hodgkin 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Istodax

Trials by Country

Trials by Country for Istodax
Location Trials
United States 90
France 3
United Kingdom 2
Korea, Republic of 2
Australia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Istodax
Location Trials
New York 9
California 9
Texas 8
Maryland 6
Illinois 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Istodax

Clinical Trial Phase

Clinical Trial Phase for Istodax
Clinical Trial Phase Trials
Phase 3 2
Phase 2 15
Phase 1/Phase 2 12
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Istodax
Clinical Trial Phase Trials
Recruiting 16
Completed 10
Terminated 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Istodax

Sponsor Name

Sponsor Name for Istodax
Sponsor Trials
National Cancer Institute (NCI) 19
Celgene Corporation 10
Celgene 5
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Istodax
Sponsor Trials
Other 36
NIH 20
Industry 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Colorcon
US Department of Justice
Accenture
McKesson
Mallinckrodt
Teva
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.